{"id":10102,"date":"2020-10-28T10:44:26","date_gmt":"2020-10-28T01:44:26","guid":{"rendered":"http:\/\/cell.brc.riken.jp\/en\/?page_id=10102"},"modified":"2021-09-13T14:01:10","modified_gmt":"2021-09-13T05:01:10","slug":"covid-19-related-cell-lone-resources","status":"publish","type":"page","link":"http:\/\/cell.brc.riken.jp\/en\/covid-19-related-cell-lone-resources","title":{"rendered":"Cell line resources for COVID-19 research"},"content":{"rendered":"

1) Efforts of RIKEN BRC promoting COVID-19 related research<\/strong><\/p>\n

RIKEN BioResource Research Center (BRC) is a unique repository in the world, as it collects and distributes bioresources of three different levels, i.e., genetic materials (genomic and cDNA clones) and cell lines of human and animal origins as well mouse strains. With this unique feature, RIKEN BRC hopes to contribute to the comprehensive research and development on COVID-19. The research and developments have been focusing on the following four subjects: 1) SARS-CoV-2 infection and proliferation, 2) Pathogenesis and host defense, 3) Disease progression to clinically severe cases and 4) Development of effective therapies of COVID-19 patients and preventive vaccines against SARS-CoV-2 infection.<\/p>\n

Lists of mouse strains and DNA clones useful for COVID-19 R&D from RIKEN BRC are available from following links:<\/p>\n

Mouse resources for COVID-19 research. (Experimental Animal Division\uff09<\/a><\/p>\n

Human genes for COVID-19 research. (Gene Engineering Division\uff09<\/a><\/p>\n

\n

2\uff09Deposited cell lines<\/strong>
\n\n\n\n\n\t\n\n\t\n\t\n\t
Reference<\/th>BRC Resource<\/th>Comment<\/th>\n<\/tr>\n<\/thead>\n
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection <\/a> \"NEW\"<\/td>RCB5391 R52_Spike<\/a> <\/td>This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone R52).<\/td>\n<\/tr>\n
RCB5392 S1D7_Spike<\/a> <\/td>This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone S1D7).<\/td>\n<\/tr>\n
RCB5393 S3D8_Spike<\/a> <\/td>This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone S3D8).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n
\n

3\uff09 Papers regarding COVID-19 research in which the cell lines we have provided were used.<\/strong>
\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
<\/td>BRC Resource<\/th><\/td>Reference<\/th>\n<\/tr>\n<\/thead>\n
1<\/td>RCB2202 293T<\/a> <\/td>Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14<\/td>Modulation of TNF-\u03b1-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-\u03b1 production and facilitates viral entry<\/a><\/td>\n<\/tr>\n
2<\/td>RCB0995 MDCK<\/a> <\/td>Clin Infect Dis. 2020 Oct 3;ciaa1517<\/td>Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19<\/a> <\/td>\n<\/tr>\n
3<\/td>RCB0535 RAW 264<\/a> <\/td>Viruses. 2020 Jun 28;12(7):699<\/td>Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2<\/a> <\/td>\n<\/tr>\n
4<\/td>RCB0988 CACO-2<\/a>
\nCSII-CMV-MCS-IRES2-Bsd<\/a> <\/td>		PLoS Pathog. 2021 Jan 21;17(1):e1009233.<\/td>SARS-CoV-2 variants with mutations at the S1\/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells<\/a><\/td>\n<\/tr>\n
5<\/td>RCB0485 LA-N-5<\/a> <\/td>Sci Rep. 2021 Feb 9;11(1):3379<\/td>Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19<\/a><\/td>\n<\/tr>\n
6<\/td>RCB2202 293T<\/a> <\/td>Cell. 2021 Jun 24;184(13):3452-3466.e18<\/td>An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies<\/a> <\/td>\n<\/tr>\n
7<\/td>RCB1902 HSC-4<\/a> <\/td>J Anat. 2021 Jun;238(6):1341-1354<\/td>Expression of SARS\u2010CoV\u20102 entry factors in human oral tissue<\/a><\/td>\n<\/tr>\n
8<\/td>RCB0209 SP2\/0-Ag14<\/a> <\/td>J Biol Chem. Jan-Jun 2021;296:100346<\/td> Potent mouse monoclonal antibodies that block SARS-CoV-2 infection <\/a> <\/td>\n<\/tr>\n
9<\/td>RCB0988 CACO-2<\/a>
\nRCB2202 293T<\/a> <\/td>		Sci Rep. 2021 Mar 8;11(1):5376<\/td> MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2<\/a> <\/td>\n<\/tr>\n
10<\/td>RCB0098 A549<\/a> <\/td>bioRxiv. June 30, 2021.<\/td> Host cellular RNA helicases regulate SARS-CoV-2 infection<\/a> <\/td>\n<\/tr>\n
11<\/td>RCB0211 MRC-5<\/a><\/td>Cell Rep Med. 2021 Jun 15;2(6):100311<\/td> Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests<\/a> <\/td>\n<\/tr>\n
12\"NEW\"<\/td>RCB2202 293T<\/a><\/td>bioRxiv. August 23, 2021<\/td>The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines<\/a> <\/td>\n<\/tr>\n
13\"NEW\"<\/td>RCB0098 A549<\/a> <\/td>Biochemical and Biophysical Research Communications.77, 5 November 2021, Pages 146-151<\/td>Air-liquid interphase culture confers SARS-CoV-2 susceptibility to A549 alveolar epithelial cells<\/a> <\/td>\n<\/tr>\n
14\"NEW\"<\/td>HPS0002 253G1<\/a> <\/td>J Toxicol Sci
\n. 2021;46(9):425-435<\/td>		Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing<\/a> <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n
\n

4\uff09 Papers regarding COVID-19 research in which the cell lines we can provide were used.<\/strong>
\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
<\/td>BRC Cell Line<\/th>Cell Line<\/th>Reference<\/th>\n<\/tr>\n<\/thead>\n
1<\/td>Vero E6
\nRCB0988 CACO-2<\/a>
\nCalu-3
\nRCB2202 293T<\/a>
\nRCB1366 HuH-7<\/a><\/td>		Vero E6
\nCaco-2
\nCalu-3
\nHEK293T
\nHuh7<\/td>		In Vitro and Animal Models for SARS-CoV-2 research<\/a><\/td>\n<\/tr>\n
2<\/td>Vero E6
\nRCB1366 HuH-7<\/a>
\nRCB2202 293T<\/a>
\nRCB0098 A549<\/a>, RCB3677 A549<\/a>
\nEFKB3<\/td>		Vero E6
\nVero
\nHUH 7.0
\n293T
\nA549
\nEFKB3<\/td>		Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States<\/a><\/td>\n<\/tr>\n
3<\/td>Vero
\nRCB0007 HeLa<\/a>, RCB3680 HeLa<\/a>
\nRCB2202 293T<\/a>
\nRCB1366 HuH-7<\/a><\/td>		Vero
\nHeLa
\nHEK293T\/F
\nHuh7<\/td>		A Thermostable mRNA Vaccine against COVID-19<\/a><\/td>\n<\/tr>\n
4<\/td>RCB1637 293<\/a>
\nRCB2202 293T<\/a>
\nRCB0098 A549<\/a>, RCB3677 A549<\/a>
\nRCB0218 MRC-5, known PDL <\/a>
\nVero E6
\nVero 81
\nRCB0007 HeLa<\/a>, RCB3680 HeLa<\/a>
\nRCB1366 HuH-7<\/a><\/td>		293
\n293T
\nA549
\nMRC5
\nVero E6
\nVero 81
\nHeLa
\nHuh7<\/td>		Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV<\/a><\/td>\n<\/tr>\n
5<\/td>RCB1648 Hep G2<\/a>
\nRCB1366 HuH-7<\/a>
\nRCB2202 293T<\/a>
\nVero
\nCHO
\nRCB0995 MDCK<\/a><\/td>		HepG2
\nHuh-7
\n293T
\nVero
\nCHO
\nMDCK<\/td>		Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2<\/a><\/td>\n<\/tr>\n
6<\/td>Vero E6
\nRCB1366 HuH-7<\/a><\/td>		Vero E6
\nHuh-7<\/td>		Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-\u03baB signaling pathway<\/a><\/td>\n<\/tr>\n
7<\/td>Vero E6
\nRCB1366 HuH-7<\/a><\/td>		Vero E6
\nHuh-7<\/td>		Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-\u03baB) signaling pathway<\/a><\/td>\n<\/tr>\n
8<\/td>Vero E6
\nRCB1366 HuH-7<\/a><\/td>		Vero E6
\nHuh-7<\/td>		Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)<\/a><\/td>\n<\/tr>\n
9<\/td>Vero E6
\nRCB1366 HuH-7<\/a><\/td>		Vero E6
\nHuh-7<\/td>		A pneumonia outbreak associated with a new coronavirus of probable bat origin<\/a><\/td>\n<\/tr>\n
10<\/td>RCB1637 293<\/a>
\nRCB1366 HuH-7<\/a>
\nRCB1423 BHK-21<\/a>
\nVero E6<\/td>		HEK293
\nHuh-7
\nBHK21
\nVero-E6<\/td>		Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKK\u03b5<\/a><\/td>\n<\/tr>\n
11<\/td>RCB0007 HeLa<\/a>, RCB3680 HeLa<\/a>
\nRCB2202 293T<\/a>
\nRCB1423 BHK-21<\/a>
\nRCB0988 CACO-2<\/a><\/td>		HeLa
\n293T
\nBHK-21
\nCaco-2<\/td>		COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome<\/a><\/td>\n<\/tr>\n
12<\/td>RCB0988 CACO-2<\/a><\/td>Caco-2<\/td>Proteomics of SARS-CoV-2-infected host cells reveals therapy targets<\/a><\/td>\n<\/tr>\n
13<\/td>RCB0988 CACO-2<\/a><\/td>Caco-2<\/td>A metabolic handbook for the COVID-19 pandemic<\/a><\/td>\n<\/tr>\n
14<\/td>RCB2202 293T<\/a>
\nRCB0098 A549<\/a>, RCB3677 A549<\/a>
\nBHK
\nRCB0988 CACO-2<\/a>
\nRCB1366 HuH-7<\/a>
\nPK-15 <\/td>		293T
\nA549
\nBHK
\nCaco-2
\nHuh-7.5
\nPK-15 <\/td>		Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses<\/a><\/td>\n<\/tr>\n
15<\/td>RCB2202 293T<\/a>
\nRCB0098 A549<\/a>, RCB3677 A549<\/a><\/td>		HEK293T
\nA549 <\/td>		Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza<\/a><\/td>\n<\/tr>\n
16<\/td>RCB2202 293T<\/a>
\nRCB0007 HeLa<\/a>, RCB3680 HeLa<\/a>
\nCalu-3
\nRCB0218 MRC-5, known PDL <\/a><\/td>		HEK293T
\nHeLa
\nCalu-3
\nMRC-5<\/td>		Cell entry mechanisms of SARS-CoV-2<\/a><\/td>\n<\/tr>\n
17<\/td>RCB2202 293T<\/a>
\nHEK293F
\nRCB0007 HeLa<\/a>, RCB3680 HeLa<\/a>
\nRCB0218 MRC-5, known PDL <\/a><\/td>		HEK293T
\nHEK293F
\nHeLa
\nMRC5 <\/td>		Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry<\/a><\/td>\n<\/tr>\n
18<\/td>RCB1366 HuH-7<\/a>
\nHuh-7.5<\/td>		Huh-7
\nHuh-7.5<\/td>		Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication<\/a><\/td>\n<\/tr>\n
19<\/td>MA104
\nRCB1637 293<\/a><\/td>		MA104
\nHEK293<\/td>		TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes<\/a><\/td>\n<\/tr>\n
20<\/td>RCB0218 MRC-5, known PDL <\/a><\/td>MRC-5 <\/td>Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells<\/a><\/td>\n<\/tr>\n
21<\/td>Fcwf-4
\nA72
\nRCB0995 MDCK<\/a>
\nDH82<\/td>		Fcwf-4
\nA72
\nMDCK
\nDH82 <\/td>		Establishment of a Virulent Full-Length cDNA Clone for Type I Feline Coronavirus Strain C3663<\/a><\/td>\n<\/tr>\n
22<\/td>GES-1
\nRCB1189 THP-1<\/a>,RCB3686 THP-1<\/a><\/td>		GES-1
\nTHP-1 <\/td>		Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n","protected":false},"excerpt":{"rendered":"

1) Efforts of RIKEN BRC promoting COVID-19 related research RIKEN BioResource Research Center (BRC) is a unique repository in the world, as it collects and distributes bioresources of three different levels, i.e., genetic materials (genomic and cDNA clones) and cell lines of human and animal origins as well mouse strains. With this unique feature, RIKEN BRC hopes to contribute to the comprehensive research and development on COVID-19. The research and developments have been focusing on the following four subjects: 1) SARS-CoV-2 infection and proliferation, 2) Pathogenesis and host defense, 3) Disease progression to clinically severe cases and 4) Development of effective therapies of COVID-19 patients and preventive vaccines against SARS-CoV-2 infection. Lists of mouse strains and DNA clones useful for COVID-19 R&D from RIKEN BRC are available from following links: Mouse resources for COVID-19 research. (Experimental Animal Division\uff09 Human genes for COVID-19 research. (Gene Engineering Division\uff09 2\uff09Deposited cell lines 3\uff09 Papers regarding COVID-19 research in which the cell lines we have provided were used. 4\uff09 Papers regarding COVID-19 research in which the cell lines we can provide were used.<\/p>\n","protected":false},"author":15,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_analysis_target_kw":"","footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-10102","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/comments?post=10102"}],"version-history":[{"count":9,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10102\/revisions"}],"predecessor-version":[{"id":10320,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10102\/revisions\/10320"}],"wp:attachment":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/media?parent=10102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}